PRE-EVENT SURVEY – APAC Kick Off Meeting

Our tagline for the APAC Kick-off Meeting is Something Evolving, and we have chosen the key words INSPIRE , FOCUS and EMBRACE to reflect our APAC vision and strategic direction in 2022. Together we will explore what these keywords mean to us at work, and how you think they will enable BioMarin to flourish in 2022.

In the meantime, please take a moment to share your thoughts – we want to know what Something Evolving 2022 means to you! We would also like you to share with us whom you think should be recognized for embodying the essence of INSPIRE, FOCUS and EMBRACE!

The results from this pre-meeting survey may be used by the working group to aid the development of future materials.

“It is not the strongest of the species that survive, but the ones that are responsive to change.” Charles Darwin

The COVID-19 pandemic has transformed our lives and business forever. We made step change advances during 2021 and to EVOLVE in 2022, we encourage you to reflect and share your learnings.

First Name *

Last Name *

Q1. How has your working practice transformed the most during 2021? (please only select one option) *

The rapid switch from face-to-face business to hybrid working
The ongoing digitalization of the healthcare sector
The continuous risk management as new variants of SARS-CoV-2 virus appeared

Q2. Reflecting on your experiences of 2021, how will BioMarin APAC EVOLVE in 2022? *

Q3. Which person or team do you believe is helping BioMarin truly EVOLVE to maximize on the opportunities of 2022? *

Q4. Please provide reason(s) for your answer in Q3. *

In 2022, we will INSPIRE each other to do better by leveraging the hybrid business model, digitalizing our customer engagement and embracing our fit-for-growth mindset. Please share your thoughts on the following questions.

Q1. What will be the biggest opportunity for BioMarin in 2022? (please only select one option) *

Hybrid ways of working and digitalization of patient/physician engagement
Product launches in Achondroplasia and Hemophilia A
Securing market leadership for the existing product pipeline

Q2. What will INSPIRE you to maximize on the opportunities that BioMarin are facing in 2022? *

Q3. Which person or team INSPIRES you to do better? *

Q4. Please provide reason(s) for your answer in Q3. *

2022 is a critical year for the regional BioMarin teams and by setting our priorities in new product launches and securing market leadership for existing products we will ensure Targeted, Efficient and Effective operations. Please share your thoughts on the following questions.

Q1. Please select the top three brands that you believe are most important to BioMarin's portfolio in the 2022 healthcare landscape. *

Brineura for Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease)
ROCTAVIAN for Hemophilia A
Kuvan for Phenylketonuria (PKU)
Vimizim for Morquio A syndrome (MPS IVA)
Naglazyme for Maroteaux-Lamy syndrome (MPS VI)
VOXZOGO for Achondroplasia
Palynziq for Phenylketonuria (PKU)

Q2. Please select the top three brands that you believe will be most important in the healthcare landscape in 5 years' time. *

Brineura for Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease)
ROCTAVIAN for Hemophilia A
Kuvan for Phenylketonuria (PKU)
Vimizim for Morquio A syndrome (MPS IVA)
Naglazyme for Maroteaux-Lamy syndrome (MPS VI)
VOXZOGO for Achondroplasia
Palynziq for Phenylketonuria (PKU)

Q3. What will be your FOCUS in 2022? *

Q4. Which person or team is FOCUSED delivering our goals in 2022? *

Q5. Please provide reason(s) for your answer in Q4. *

Achondroplasia and Hemophilia A are our key therapy areas for 2022 and it is critical that we embrace the APAC Core Enablers to meet business objectives and deliver strong product launches in Asia Pacific. Please share your thoughts on the following questions.

Q1. Which of the following statements are true for Achondroplasia? (please tick all that apply) *

Achondroplasia occurs as a result of a spontaneous genetic mutation in approximately 80% of patients
Achondroplasia is a preventable disorder
The primary features of Achondroplasia are short-limbed dwarfism and short upper arms
Achondroplasia only occurs as a heritable genetic condition

Q2. What is the global incidence rate for Achondroplasia? *

1 in 20,000–30,000 live births (approximately)
1 in 1,000–10,000 live births (approximately)
1 in 100–1,000 live births (approximately)

Q3. What treatments are available for Achondroplasia? *

Q4. Which of the following statements are true for Hemophilia A? (please tick all that apply) *

Hemophilia A is a sex-linked recessive disorder
Hemophilia A is caused by deficiency in factor IX
The primary feature of Hemophilia A is bleeding that does not stop
Hemophilia only affects males

Q5. What is the global incidence rate for Hemophilia A? *

1 in 20,000–30,000 live births (approximately)
1 in 1,000–10,000 live births (approximately)
1 in 100–1,000 live births (approximately)

Q6. What treatments are available for Hemophilia A? *

Q7. What will you EMBRACE in 2022? *

Q8. Which person or team EMBRACES new ways of working? *

Q9. Please provide reason(s) for your answer in Q8. *